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Background: Small cardiac tissue engineering constructs show promise for limiting post-infarct sequelae in
animal models. This study sought to scale-up a 2-cm2 preclinical construct into a human-size advanced ther-
apy medicinal product (ATMP; PeriCord), and to test it in a first-in-human implantation.
Methods: The PeriCord is a clinical-size (1216 cm2) decellularised pericardial matrix colonised with human
viable Wharton’s jelly-derived mesenchymal stromal cells (WJ-MSCs). WJ-MSCs expanded following good
manufacturing practices (GMP) met safety and quality standards regarding the number of cumulative popu-
lation doublings, genomic stability, and sterility. Human decellularised pericardial scaffolds were tested for
DNA content, matrix stiffness, pore size, and absence of microbiological growth.
Findings: PeriCord implantation was surgically performed on a large non-revascularisable scar in the inferior
wall of a 63-year-old male patient. Coronary artery bypass grafting was concomitantly performed in the
non-infarcted area. At implantation, the 16-cm2 pericardial scaffold contained 12¢5 £ 106 viable WJ-MSCs
(85¢4% cell viability; <0¢51 endotoxin units (EU)/mL). Intraoperative PeriCord delivery was expeditious, and
secured with surgical glue. The post-operative course showed non-adverse reaction to the PeriCord, without
requiring host immunosuppression. The three-month clinical follow-up was uneventful, and three-month
cardiac magnetic resonance imaging showed ~9% reduction in scar mass in the treated area.
Interpretation: This preliminary report describes the development of a scalable clinical-size allogeneic Peri-
Cord cardiac bioimplant, and its first-in-human implantation.
Funding: La Marato de TV3 Foundation, Government of Catalonia, Catalan Society of Cardiology, “La Caixa”
Banking Foundation, Spanish Ministry of Science, Innovation and Universities, Institute of Health Carlos III,
and the European Regional Development Fund.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
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Evidence before this study
MI sequelae remain a major cause of morbidity and mortality.
Small-sized cardiac tissue engineered grafts proved safe and
effective in the MI swine model.
Added value of this study
Here we developed and performed the first-in-human surgery
of a scalable clinical-size PeriCord cardiac bioimplant.
Implications of all the available evidence
The PeriCord, composed of human WJ-MSCs within decellular-
ised pericardium, was feasible and preliminarily safe, without
requirement of host immunosuppression after implantation.
Long-term follow up and completion of the PERISCOPE trial
will confirm the value of this first-in-class PeriCord cardiac
bioimplant.Fig. 1. Schematic of the two components of the PeriCord bioimplant, human WJ-MSCs
and human decellularised pericardium. The PeriCord was safely implanted in a first-
in-human patient.1. Introduction
Myocardial infarction (MI) causes irreversible cardiac muscle loss,
non-contractile scar formation, and, ultimately, a maladaptive
adverse ventricular remodelling resulting in end-stage ischemic
heart failure [1]. Over recent decades, many small-scale clinical trials
have tested cell-based therapies using distinct cell sources, with the
aim of regenerating infarcted hearts [25]. Many of these trials have
reported only modest improvements in cardiac function, which are
unlikely to be clinically relevant [6].
Main sources of mesenchymal stromal cells (MSCs) include bone
marrow, adipose tissue, and Wharton’s jelly from the umbilical cord
discarded after birth. Notably, large quantities of allogeneic MSCs can
be most easily collected from Wharton’s jelly, and these Wharton’s
jelly-derived MSCs (WJ-MSCs) are more primitive than MSCs derived
from more mature tissue sources, exhibiting intermediate properties
between those of embryonic and adult stem cells [7]. Moreover, WJ-
MSCs have a lower risk of carrying somatic mutations, extensive
expansion capacity in culture, immunological immaturity, and immu-
nomodulatory properties, making them optimal candidates for allo-
geneic cell therapy. Nevertheless, the mechanisms of action of MSCs
are not fully deciphered. MSCs are associated with regenerative and
immunomodulatory capabilities, including monocyte modulation
toward an anti-inflammatory phenotype that facilitates tissue repair
[8,9]. We observed that WJ-MSCs polarise monocytes towards a regu-
latory M2 phenotype, and strongly inhibit inflammatory responses of
stimulated allogeneic T cells [10,11].
Cardiac tissue engineering is a therapeutic strategy that involves
delivery of both cells and supportive biomaterials into injured myo-
cardium, thus improving cell retention and survival compared with
direct cell injection delivery [12,13]. We previously demonstrated
that a small (2 cm2) engineered preclinical cardiac graft comprising
human decellularised pericardium and MSCs was safe and effective
in an MI porcine model [1416]. Once implanted over the ischemic
myocardium, the graft became vascularised and innervated, promot-
ing damaged tissue revascularisation, reducing infarct size, amelio-
rating the adverse remodelling process and fibrosis progression, and
ultimately improving cardiac function [1416].
In the present study, we describe the translational process to the
clinic, including graft scalability and good manufacturing practice
(GMP) biofabrication, from a small-size preclinical construct to anallogeneic investigational advanced therapy medicinal product
(ATMP; named PeriCord). We also report preliminary safety data
from the first PeriCord implantation performed in a roll-in patient
from the ongoing phase I PERISCOPE (the PERIcardial matrix with
mesenchymal Stem Cells fOr the treatment of PatiEnts with infarcted
myocardial tissue) clinical trial (EudraCT N°. 2018-001964-49; Clini-
calTrials.gov identifier: NCT03798353).
2. Materials and methods
2.1. Rational of the study
The main objective of this study was to scale up a small-size pre-
clinical construct into a human-size allogeneic investigational ATMP,
named PeriCord, following GMP-compliant procedures and to test it
in a first-in-human implantation in the context of the PERISCOPE
clinical trial (Fig. 1). This novel ATMP combines WJ-MSCs as active
ingredient and human decellularised, lyophilised, and sterilised peri-
cardium, acting as a cell supportive material (vehicle) for surgical
implantation.
Umbilical cord (UC) samples were collected within the Concordia
Program (http://www.bancsang.net/professionals/en_concordia) with
appropriate donor informed consent. UC-mesenchymal stromal cells
(MSCs) were derived from the Wharton’s jelly (WJ) in qualified areas of
Blood and Tissue Bank of Catalonia (BST, Barcelona), following GMP-
compliant procedures. Human pericardium samples were obtained from
Table 1
Acceptance criteria for the manufacturing of clinical-grade WJ-MSCs.
In-process
quality control
Acceptance
criteria
Manufacturing
process
UC blood Serology: HBsAg, HIV I/II, Lues
(TPHA), Chagas, anti-HBc,
HCV, anti-HTLV I/II, NAT
(HCV-HIV, HBV)
Negative
WJ-MSC expansion
step and scale-up
to DP
Dose 2¢5 £ 107 § 20%
viable cells/cryotube
Viability 70%
Karyotype Non-chromosomal
abnormalities
CD105+/CD45 (%) 95%
CD73+/CD31 (%) 95%
CD90+ (%) 95%
HLA-DR Informative*
Mycoplasma Negative
Endotoxin 1 EU/mL
Sterility Sterile
Adventitious virus Negative
Immunomodulation
(Potency assay)
>30% Inhibition
of PBMC proliferation
Note: DP, drug product; EU, endotoxin units; HBsAg, hepatitis B surface antigen;
HBc, hepatitis B core antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HTLV,
human T-cell leukemia-lymphoma virus; HIV, human immunodeficiency virus;
NAT, nucleic acid test; PBMC, peripheral blood mononuclear cell; TPHA, Treponema
pallidum hemagglutination assay; UC, umbilical cord; WJ-MSCs, Wharton’s jelly
mesenchymal stromal cells.
* HLA-DR for informative purposes only.
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with European Tissue and Cell Directives (2004/23/CE, 2006/17/CE, and
2006/86/CE), and with the local legal requirements and the Laws for the
Development and Applications of Organ Transplants. Informed consent
was obtained for clinical application and/or applied research.
With respect to active ingredient, we obtained n = 4 batches of clin-
ical-grade WJ-MSCs. In all cases, serological, microbiological, and
adventitious virus testing, karyotyping, sterility, Mycoplasma, endo-
toxin levels, phenotypic profiling and immunomodulatory assay, were
performed throughout manufacturing process in order to confirm WJ-
MSCs’ identity and potency, to ensure batch-to-batch bioequivalence,
and to guarantee suitability for clinical use. Viability of initial thawed
WJ-MSCs (n = 37), following sucrose resuspension (n = 37) and after
16 h at 28 °C (n = 20) were also analysed by flow cytometry.
Concerning vehicle component, a total of n = 35 human pericardia
were cut and decellularised. Different square pieces of ~16 cm2 and
~1 cm2 obtained from each pericardium were randomly assigned to
different experimental sets, as follows: n = 5 pieces, to measure the
effect of decellularisation on pericardial matrix dimensions; n = 4 pairs
of both sizes, to quantify DNA residual content after decellularisation;
n = 4 pieces, for histological and immunohistochemical analysis; n = 4
pairs of both sizes, for mechanical testing; n = 11 pieces, to analyse
pore size and roundness ratio in decellularised pericardial matrices;
and n = 4 pairs of both sizes, for validation of the final decellularisation
protocol. Upon validation of decellularisation, n = 3 pericardia were
used to validate manufacturing procedure of the vehicle (final matrix),
including serological and microbiological testing, sterility assessment,
final quadrangular size, residual moisture, and citotoxicity testing.
During the scale-up process, n = 37 matrix colonisations were per-
formed using post-thawed sucrose-conditioned WJ-MSCs. After
sequential cell seeding, WJ-MSCs viability was verified in samples of
both ~16 cm2 and ~1 cm2 from n = 3 vehicle batches. Following the
defined manufacturing protocol, WJ-MSCs’ colonisation efficiency
(n = 47), dose range (n = 47), and viability (n = 27) were determined
in the finished product (FP). Finally, PeriCord’s manufacturing process
(n = 4), stability (n = 3) and transportation (n = 3) were also validated
at room temperature (RT) before the first PeriCord manufactured to
be implanted in a roll-in patient of the PERISCOPE trial.
2.2. Investigational medicinal product: the PeriCord
2.2.1. Active ingredient: clinical-grade WJ-MSCs
WJ-MSCs were derived from specifically donated umbilical cord
tissue following previously described GMP-compliant procedures
[17] in the classified areas of the Blood and Tissue Bank of Catalonia
(BST; Barcelona, Spain). Briefly, clinical-grade WJ-MSCs were
obtained using a two-tiered cell banking system comprising an initial
master cell bank (MCB), and a second cell bank, named drug product
(DP), containing ready-to-use pure WJ-MSCs. Immediately after cell
expansion, DP was cryopreserved in units containing 2¢5 £ 107 § 20%
cells/cryovial in Plasmalyte148 (Baxter, Deerfield, IL, USA) supple-
mented with 4% w/v human serum albumin (Grifols, Barcelona,
Spain) and 10% v/v dimethyl sulfoxide (Cryoserv, Bioniche Pharma,
Lake Forest, IL, USA), and stored until PeriCord manufacturing.
All DP batches were assayed for identity (phenotype) and potency
(immunomodulatory potential) to ensure bioequivalence between
batches. Phenotype was evaluated by flow cytometry. WJ-MSCs were
immunostained with specific antibodies against the surface markers
CD31, CD45, CD73, CD90, CD105, and HLA-DR, based on the mesenchy-
mal identity criteria established by the International Society for Cellular
Therapy (details in Supplementary Materials) [18]. Cell number and via-
bility were determined by Perfect-Count MicrospheresTM (Cytognos,
Salamanca, Spain) microbeads and 7-amino-actinomycin D (BD Bio-
sciences, Franklin Lakes, NJ, USA) exclusion method, respectively, fol-
lowing manufacturer’s instructions. Acquisition was performed using a
FACSCaliburTM flow cytometer (BD, Franklin Lakes, NJ, USA), and dataanalysed with BD CellQuestTM Pro-software (version 5.2.1.; BD Bioscien-
ces, Franklin Lakes, NJ, USA). WJ-MSC potency was evaluated using
peripheral blood mononuclear cells (PBMCs) from healthy blood donors
(BST), obtained by density gradient (Histopaque-1077; Sigma-Aldrich
Inc., St. Louis, MO, USA). To assess cell proliferation, isolated PBMCs
were labelled with carboxy-fluorescein diacetate succinimidyl ester
(CFSE; Invitrogen, Carlsbad, CA, USA), as previously described [19].
The clinical-grade WJ-MSCs met several safety and quality stand-
ards with regards to number of cumulative population doublings,
genomic stability, and sterility, which were examined according to
the investigational medicinal product dossier approved by the Span-
ish Agency of Medicines and Medical Devices (AEMPS; PEI16-017).
Table 1 summarises the acceptance criteria for all the in-process con-
trols during clinical-grade WJ-MSCs manufacturing.2.2.2. Vehicle: decellularised, lyophilised and sterilised human
pericardium
Human pericardium samples (n = 35) were obtained from
deceased donors within 24 h post-death, and frozen at 80 °C. Each
pericardium was cut into square pieces of 4 £ 4 cm (~16 cm2) and
1 £ 1 cm (~1 cm2).
Decellularisation in the BST-qualified areas was performed as previ-
ously reported by our group [14], with some modifications compatible
with the quality-by-design approach to ensure human tissue quality
(see Supplementary Materials). The procedure was validated using two
paired quadrangular pieces of pericardium (n = 4 pairs) to demonstrate
equivalence between both sizes. Acceptance criteria for each analysed
parameter in decellularised pericardia based on the former preclinical
construct properties, included DNA content, matrix stiffness, pore size,
and microbiological growth (BACT/ALERT method; BioMerieux, Inc.,
Durham, NC, USA) (Supplementary Table 1).
Each vehicle batch contained two fragments (~16 cm2 and ~1 cm2) of
human decellularised, lyophilised, and sterilised pericardium. The
~16 cm2 was used for PeriCord manufacturing, and the ~1 cm2 for an in-
process quality control (QC; cell viability assessment). Vehicle batch
release criteria included negative serological (same as indicated in
Table 1 for umbilical cord blood) and microbiological testing of the
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system (BD, Franklin Lakes, NJ, USA), final regular quadrangular size of
1216 cm2, homogeneous density, lack of orifices, residual moisture
<10%, and gamma irradiation (2535 kGy).
2.2.3. PeriCord manufacturing
The development and design of PeriCord (FP) had our preclinical
experience as starting point. Different colonisation strategies were
assayed in order to replicate the composition of the preclinical con-
struct (2 cm2) in a larger scale (1216 cm2). A final protocolFig. 2. Schematic of clinical-grade PeriCord manufacconsisting in a sequential cell seeding by sectors onto the vehicle was
chosen. Then, PeriCord was an investigational ATMP defined as a
human decellularised, lyophilised, and sterilised pericardial matrix
(1216 cm2) colonised with viable WJ-MSCs in 0.15% v/v PuraStat
(3-D Matrix Inc., Tokyo, Japan) and 10% w/v sucrose (Sigma-Aldrich
Inc., St. Louis, MO, USA). PeriCord was manufactured at GMP-certified
facilities (BST), following AEMPS-approved procedures (PEI18-140).
PeriCord biofabrication involved multiple steps and in-process con-
trols performed on the same day as FP batch release for clinical use
(Fig. 2). The main steps were vehicle immobilisation in the primaryturing process, and established in-process QCs.
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dose adjustment, vehicle colonisation, and final packaging in a tem-
perature-monitored triple-container system with Plasmalyte148
solution for PeriCord transportation to the hospital before implanta-
tion (details in Supplementary Materials). A small-scale (~1 cm2) rep-
lica of each FP was proportionately manufactured in parallel, for in-
process cell viability assessment. We also performed validation of the
scale-up procedure, PeriCord manufacturing process, in-process QCs,
and FP stability and transportation. In-process QC strategy in the FP
include: WJ-MSCs dose calculation, based on cell count method; the
microbiological control, endotoxin levels, and Mycoplasma test on
washing supernatants (as previously described for clinical grade WJ-
MSCs batch release); environmental controls (particles and microbi-
ology); and the viability of cells colonising matrix, determined by
LIVE/DEADTM method in the small-scale replica (Fig. 2).The accep-
tance criteria for initial PeriCord batch certification comprised a dose
range of (715) £ 106 total viable WJ-MSCs, 70% viability and endo-
toxin levels 4 endotoxin units (EU)/mL.
PeriCord stability was determined by analysing viability of WJ-
MSCs colonising matrix with LIVE/DEADTM method at different time
points (from 0 to 96 h), maintaining the FP in the final packaging at
RT (n = 3). PeriCord transportation was also validated to evaluate the
impact of shipment on the final cell dose. Thus, FP and corresponding
small-replica (n = 3 each) were shipped from BST to the Germans
Trias i Pujol University Hospital (12-km distance) at RT in a tempera-
ture-monitored container, in accordance with P650 Packaging Regu-
lations of the European Agreement Concerning the International
Carriage of Dangerous Goods by Road (ADR) for the transport of bio-
logical substances, category B (Class UN 3373).
2.3. PeriCord first-in-human surgical implantation
Here we report preliminary data for up to three months following
the PeriCord implantation in a roll-in patient from the PERISCOPE
trial. The PERISCOPE trial is a first-in-human, phase I, double-blind
(patients and clinical cardiologist), single-centre clinical trial
(NCT03798353). This study was approved by the AEMPS and the local
Ethics Committee from the Germans Trias i Pujol University Hospital
(Eudra CT No. 2018-001964-49) and follows the ethical precepts of
the Declaration of Helsinki and the Guidelines on Good Clinical Prac-
tice specific to ATMPs. The presently reported patient gave signed
informed consent prior to enrolment.
The trial will enrol a total of 12 patients with non-revascularisable
myocardial scars who are candidates for surgical revascularisation of
other myocardial areas, including two roll-in open-labelled patients,
and ten randomised patients to a control or treatment group (1:1
ratio, using a computer-generated sequence). Following inclusion in
the study (first visit), control patients will undergo coronary artery
bypass graft (CABG) for the revascularisable region(s). Treatment
patients will undergo the required CABGs and also receive PeriCord
applied by surgical glue (Glubran2, CardioLink, Barcelona, Spain)
over the non-revascularisable myocardial scar. Patients will have fol-
low-up visits at one-week post hospital discharge, three, six, and 12
months. The primary endpoint is safety, according to a combination
of clinical severe events (death or all-cause rehospitalisation) and
severe adverse reaction to the PeriCord. Safety data will be assessed
by an independent safety monitoring board. Secondary endpoints
include arrhythmias, biomarkers, MRI, and quality of life data.
2.4. Cardiac magnetic resonance imaging data acquisition and analysis
Magnetic resonance imaging (MRI) was performed in a state-of-
the-art 1.5T clinical imaging system (InteraDB System; Philips, Eind-
hoven, NL) with the patient in the supine position, and a 16-element
phased-array coil placed over the chest. Images were acquired during
breath-holds with ECG gating. We used a segmented k-space steady-state free-precession sequence [repetition time 44¢70 ms; echo time
1¢26 ms; flip angle 78°; matrix 272; spatial resolution (1¢31¢5) x
(1¢31¢5) x 8 mm, depending on the field of view] for cine imaging in
parallel short-axis (contiguous slices of 8-mm thickness covering
from base to apex), and three long-axis views of the left ventricle.
Delayed enhancement images were acquired with a segmented gra-
dient-echo inversion-recovery sequence [repetition time
600800 ms, depending on the cardiac heart rate; echo time
3¢24 ms; flip angle 25°; matrix 256; spatial resolution
1¢3 £ 1¢3 £ 8 mm] at matching cine-image slice locations 10 to
20 min after intravenous gadolinium-DTPA administration
(0¢2 mmol/kg; Gadovist, Bayer Schering Pharma AG, Berlin, Germany)
[20]. We optimised the inversion time to null the normal myocar-
dium and adjusted views per segment, and trigger delay according to
the patient’s heart rate.
All images were reviewed and analysed off-line with a specialised
post-processing software (IntelliSpace Portal, Philips, Eindhoven, NL)
by an independent operator (A.T.). Left ventricular (LV) endocardial
border (papillary muscles were excluded) were manually traced on
all short-axis cine images at the end-diastolic and end-systolic frames
to determine the LV end-diastolic and LV end-systolic volumes,
respectively. LV mass was calculated by subtracting the endocardial
volume from the epicardial volume at end diastole and then multi-
plying by the tissue density (1¢05 g/mL) [21,22].
The endocardial and epicardial contours on delayed enhancement
images were also outlined manually. Regions of interest (ROIs) were
then manually traced in the hyper-enhanced area at place of maxi-
mum signal intensity, and in the normal-appearing remote myocar-
dium. As previously described, the areas of hyper-enhancing
myocardium were then automatically segmented by using a full-
width at half-maximum (FWHM) algorithm [23,24]. Two corrections
were required for all automated ROIs. First, microvascular obstruction
(defined as hypointensity within a hyperintense region in patients
with infarctions) was adjusted to be included as late gadolinium
enhancement if present. Second, any obvious blood pool or pericar-
dial partial volume and artefacts were further removed from the ROI.
Scar volume for each slice was calculated as: area scar £ slice
thickness. The scar mass was expressed as total scar volume £ 1¢05 g.
The scar percentage of myocardium was also expressed as a percent-
age of the total myocardial volume: volume scar/volume
myocardium £ 100.
2.5. Statistical analysis
Data are presented as mean § SEM. Statistical analyses for cyto-
toxicity experiments were performed using the independent Stu-
dent’s t-test. The paired sample t-test was used to analyse vehicle
area reduction and vehicle size comparisons (DNA content, pore size,
and roundness in 16 cm2 vs. 1 cm2). One-way ANOVA with Tukey’s
post-hoc correction for multiple comparisons were used for DNA
content, pore size, and mechanical data. Non-parametric Friedman
and Wilcoxon Signed-Rank tests were used to assess differences in
cell viability by sequential colonisation strategy and vehicle size,
respectively. Data were analysed using SPSS 21.0.0.0 (SPSS Inc., Chi-
cago, IL, USA), GraphPad Prism 6 (GraphPad Software, San Diego, CA,
USA), and SigmaPlot 13 (Systat Software Inc., San Jose, CA, USA). Val-
ues were considered significant when p < 0¢05.
3. Results
3.1. Clinical-grade WJ-MSC production
We obtained clinical grade WJ-MSCs with a 100% success rate
(n = 4), yielding a median of 6¢4 £ 108 WJ-MSCs, with 30 § 2 days
from initial cord tissue explant culture to DP unit cryopreservation
(Fig. 3A). In detail, MCB involved the isolation, selective expansion,
Fig. 3. Clinical-grade WJ-MSC characterisation. (a) Representative microscopic image of expanded WJ-MSCs culture. Scale bar = 100mm. (b) Normal karyotype of a DP, correspond-
ing to a representative cell line. (c) Immunophenotypic characteristics of four clinical-grade cell batches and average expression (mean § SEM). (d) Immunomodulation potential
measured in four batches of clinical-grade WJ-MSCs, as the capacity to inhibit proliferation of polyclonal stimulated lymphocytes. (e) Microscopic images showing stimulated PBMC
clumping, and clump reduction when co-cultured with WJ-MSCs. Arrowheads indicate clumps. Scale bars = 100 mm. PBMCs, peripheral blood mononuclear cells; WJ-MSCs, Whar-
ton’s jelly mesenchymal stromal cells.
Table 2
Specifications for preclinical construct and finished PeriCord human bioimplant.
Preclinical
construct
PeriCord
human bioimplant
Active ingredient
Viable cells Porcine MSCs HumanWJ-MSCs
Density 0¢875 £ 106/cm2 (0¢620¢93) £ 106/cm2
Dose 1¢75 £ 106 cells (715) £ 106 cells
Viability 70% 70%
Excipient
Definition Vehicle Vehicle
Hydrogel PuraMatrixTM Hydrogel PuraStatTM
Sucrose Sucrose
Phosphate buffered saline Plasmalyte148
Vehicle Decellularised, lyophilised,
and irradiated human
pericardium
Decellularised, lyophilised,
and irradiated human
pericardium
Vehicle size 2 cm2 1216 cm2
Note: MSCs, mesenchymal stromal cells; WJ-MSCs, Wharton’s jelly mesenchymal
stromal cells.
6 C. Prat-Vidal et al. / EBioMedicine 54 (2020) 102729and cryopreservation of WJ-MSCs. DP encompassed thawing a cryo-
preserved MCB unit, cell culture expansion, cryopreservation, and
QCs. Various in-process controls, including microbiological testing,
were performed throughout these steps (Table 1). After expansion,
we evaluated sterility using European Pharmacopeia (Eur. Ph.),Myco-
plasma, and endotoxin tests. In all cell batch productions, a cryopre-
served DP unit was generated for use as a control tube for the freeze-
thawing process, potency assay, adventitious virus testing, and kar-
yotyping. Observing no evidence of turbidity in any step of the three
assayed runs in the Media Fill procedure, we considered the produc-
tion process aseptic.
Table 2
DP viability was 97¢2 § 0¢5% (n = 4), with undetectable levels of
endotoxins and Mycoplasma DNA. No bacterial contamination or
adventitious viruses were detected. To exclude any potential effects
of the scale-up process on WJ-MSC genetic stability, we determined
G-banding karyotypes at early and late passages. At the cytogenetic
level, all karyotypes showed unaltered patterns after accumulating
21 § 3 cumulative population doublings (Fig. 3B). Phenotypic profil-
ing revealed a MSC-like pattern, with over 95% of cells strongly posi-
tive for CD73, CD90, and CD105, and negative for CD31, CD45, and
HLA-DR (Fig. 3C). WJ-MSCs’ mesenchymal identity was conserved
throughout expansion culture, with no differences observed between
initial and late passages.
WJ-MSCs of different cell lines or passage numbers did not differ
in their ability to inhibit proliferation of polyclonal activated lympho-
cytes. In all cases, clinical grade WJ-MSCs could inhibit proliferation
by 88¢7 § 6¢2% (range, 73¢899¢9% inhibition, n = 4; Fig. 3D). At themicroscopic level, stimulated PBMCs clusters were reduced only
when WJ-MSCs were present, correlating to the immunopotency
results obtained (Fig. 3E).
3.2. Decellularised pericardial matrix processing
The decellularisation protocol generated similar pale pericardial
fragments, regardless of the initial sample size (Fig. 4AC, E, I, and K).
Fig. 4. Pericardial tissue decellularisation. (a) Photograph showing native pericardium from deceased donor. (b) Native pericardium after dissection of superficial adhered adipose
tissue. (c) Decellularised pericardial scaffolds after detergent treatment. Scale bars = 1 cm. (d and e) Masson’s trichrome staining of native (d) and decellularised (e) pericardium.
Scale bars = 100 mm. (f and g) SEM-determined ultrastructure of native pericardium (f) and acellular pericardial matrix (g). Scale bars = 100 mm. (hk) Representative images of
native pericardium (h and j) and decellularised pericardial scaffolds (i and k), showing immunostaining for col-III and elastin (both grey), and cell actin filaments with phalloidin
(Phal, red). Nuclei were counterstained with DAPI (blue). Scale bars = 20mm. (l) Genomic DNA quantification of native tissue, and 16 cm2 and 1 cm2 decellularised scaffolds, normal-
ised to scaffold dry weight. *p < 0¢05 [paired Student’s t-test], native pericardium vs. decellularised scaffold. (m) Pore size measurements in decellularised pericardial scaffolds and
vehicle. (n) Microscopic stiffness (Em) of pericardium measured with AFM in native tissues and decellularised scaffolds (n = 4). (o) Macroscopic stiffness (EM) of pericardium mea-
sured at 20% stretch using tensile testing, for the same tissue conditions. Dashed lines in the graphs indicate the acceptance criteria for each parameter analysed. All data presented
as mean § SEM. *p = 0¢046 [One-way ANOVA and Tukey’s post-hoc correction for multiple comparisons], between vehicle vs. decellularised pericardium (1 cm2). (For interpretation
of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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detectable cells and nuclei (Fig. 4D and E), and immunostaining
revealed no cytoskeletal elements or cellular nuclei (Fig. 4HK).
Decellularised scaffolds maintained the intrinsic organisation and
spatial three-dimensional distribution of the native matrix fibrils
(Fig. 4F and G), and the representative matrix proteins elastin, and
type-III collagen were properly stained, indicating preservation of
extracellular matrix (ECM) protein components (Fig. 4I and K). Vali-
dation of decellularisation was performed by processing four conse-
cutive pericardia, including samples of both ~16 cm2 and ~1 cm2. The
four decellularised batches met the proposed acceptance criteria for
all analysed parameters (Supplementary Table 1). DNA content was
<50 ng/mg of decellularised dry tissue, reaching a reduction of nearly
100% in the final decellularised matrix (Fig. 4L). These minimal DNA
levels confirmed matrix suitability for clinical use, thus avoiding pos-
sible adverse cell and host responses [25]. Matrix dimensions did not
significantly differ after decellularisation (2¢8 § 2¢9% global area
reduction; n = 5, p = 0¢209 [paired Student’s t-test]). The ~16-cm2 and
~1-cm2 decellularised scaffolds exhibited similar pore size
(26¢0 § 0¢6mm vs. 27¢3 § 1¢2mm; p = 0¢351 [paired Student’s t-test])
(Fig. 4M), and pore roundness ratio (0¢5 § 0¢006 vs. 0¢5 § 0¢01;
p = 0¢230 [paired Student’s t-test]). Compared to decellularised scaf-
folds, the vehicle exhibited smaller pore size (23¢1 § 1¢0 mm) and
bigger roundness ratio (0¢6 § 0¢01), but both parameters met the
acceptance criteria demonstrating matrix equivalence.We evaluated the mechanical properties of pericardial tissue on two
scales: micromechanics using atomic force microscopy (AFM) (Fig. 4N),
and macromechanics by tensile testing (Fig. 4O). ECM stiffness did not
differ after decellularisation compared to native pericardium at the
microscale or macroscale. Trehalose incubation, lyophilisation, and steri-
lisation for obtaining the vehicle induced a slight decrease (~25%) in peri-
cardial scaffold stiffness at the microscale, and a smaller (~15%) non-
significant softening at themacroscale (p = 0¢384 [one-way ANOVA]).
Upon validation of the decellularisation protocol, we next vali-
dated the manufacture design of the final matrix (vehicle) by process-
ing three consecutive pericardia. The three batches met the proposed
acceptance criteria for all analysed parameters in terms of serological
and microbiological testing, sterility assessment, final quadrangular
size, and residual moisture. Cytotoxicity testing using decellularised,
lyophilised, and sterilised pericardial extracts revealed no cytotoxic
effects on cell viability (>70%, n = 3; p < 0¢001 [Student’s t-test]),
demonstrating the suitability of the vehicle for clinical use.
3.3. PeriCord cardiac bioimplant: scale-up and manufacturing process
PeriCord with clinically relevant dimensions (1216 cm2) comprised
human allogeneicWJ-MSCs colonising a human allogeneic decellularised
pericardium. Manufacturing process of PeriCord is schematically dis-
played in Fig. 1. Matrix colonisations were performed from post-thawed
sucrose-conditioned cells (2¢6 £ 107 § 0¢1 £ 107 WJ-MSCs/mL; n = 37).
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lowing sucrose resuspension (92¢4 § 1¢0%), and remained within prod-
uct specifications even after 16 h at 28 °C (88¢8 § 1¢6%; n = 20). Cell
viability was verified after seeding in both FP (1216 cm2) and small-
scale replica (1 cm2), revealing no significant differences in WJ-MSCs’
viability when the same post-thawed and sucrose-conditioned cells
were seeded into three different matrix batches (FP: 79¢6 § 1¢2%; small-
scale replica: 78¢0 § 1¢1%; p = 0¢50 [paired Student’s t-test]) (Fig. 5A).
Viable cells colonising matrix were also calculated, and no difference
between both sizes was observed (Fig. 5B). Moreover, cell viability did
not change during sequential cell seeding on different matrix sectors
(n = 3 independent matrix batches; p = 0¢3 [Friedman test]). Following
the defined manufacturing protocol, WJ-MSCs’ viability in the FP was
83¢1§ 0¢01% (n = 27).
WJ-MSCs’ seeding efficiency and dose range in the FP were deter-
mined (n = 47) based on the cell retention capacity of pericardial
matrices, analysed by calculating the difference between the initial
seeded WJ-MSCs and the total recovered cells after pH-balancing
washes detailed in the PeriCord manufacturing process. Average WJ-
MSCs retention was >90%, corresponding to a density range of
(0¢620¢93) £ 106 total viable WJ-MSCs/cm2, defining a dose in the
range of (715) £ 106 total viable WJ-MSCs/FP.
To validate PeriCord stability in the final packaging, we analysed
WJ-MSC viability at different time-points, maintaining the FP at RTFig. 5. PeriCord cardiac bioimplant. (a) Cell viability after colonisation was not significantly d
ble colonising cells per cm2 was also similar in both matrix sizes. (c) Stability testing of PeriC
method (n = 3). (d) Transport validation of three PeriCord batches and corresponding small-s
pH-balancing washes during manufacturing (pre-transportation), and in the Plasmalyte148
mary packaging. (g and h) Secondary sterile packaging containing Plasmalyte148 solution. ((n = 3). PeriCord RT stability period in its final container was defined
as the maximum period for maintenance of WJ-MSCs viability at
70% (product specification) and was set at 18 h (Fig. 5C).
To evaluate the impact of PeriCord transportation on the cell dose,
FP and corresponding small-scale replica (n = 3 each) were manufac-
tured and transported from BST to the Germans Trias i Pujol Univer-
sity Hospital (12-km distance). After transportation, the transport
solution (Plasmalyte148) was recovered, and the cells counted by
flow cytometry. The WJ-MSC dose defined in the batch release was
conserved by 98¢5% after transport (maximum variation, 4¢3%; aver-
age dose loss, 1¢5%) (Fig. 5DI).
To validate the manufacture, three consecutive PeriCord batches
were processed, all of which met the acceptance criteria for cell dose
and viability. Sterility and Mycoplasma test were negative or unde-
tectable, and endotoxin levels were <4 EU/mL for all FPs. Environ-
mental microbial controls, pressure levels in qualified areas, and the
number of particles fell within the operational range. No other rele-
vant incidences were reported.
3.4. PeriCord cardiac bioimplant: first-in-human patient implantation
PeriCord was implanted in a 63-year-old male patient who suffered
an inferior myocardial infarct in 2004, which was conservatively
treated. He had a history of tobacco abuse, dyslipidaemia, and mildifferent between ~16-cm2 and ~1-cm2 matrices (n = 3 each). (b) Absolute number of via-
ord in final packaging at RT by determining WJ-MSCs’ viability using the LIVE/DEADTM
cale replicas. Colonisation percentage was determined by quantifying cells in recovered
solution post-transportation. PeriCord (e) and small-replica (f) immobilised in the pri-
i) A third container used for PeriCord transport.
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syndrome. In March 2019, he presented progressive angina, and coro-
nary angiography showed three-vessel disease, with an occluded right
coronary artery, unsuitable for revascularisation. Cardiac MRI showed
transmural basal and mid inferior late gadolinium enhancement with
subendocardial extension towards the septum and lateral wall (scar
mass = 7¢8 g, scar sizescar mass normalised by total LV mass- = 5¢7%)
(Fig. 6E). LV ejection fraction was 40%, with LV end-diastolic volume
177 mL and LV end-systolic volume 106 mL. Having a clear indication
for revascularisation of the non-infarcted areas, the patient was offered
PeriCord implantation in addition to the planned CABG. After receiving
extensive information about the procedure, he gave written informed
consent. The first PeriCord manufactured for patient implantation con-
tained 12¢5£ 106 viableWJ-MSCs in a 16-cm2 pericardial scaffold (via-
bility, 85¢4%; <0¢51 EU/mL) (Fig. 6A). Fig. 6B shows the inferior infarct
during open-chest surgery, where the PeriCord was applied and
secured with surgical glue at the four edges (Fig. 6C and D, and Supple-
mentary Video 1). The patient underwent CABG to the non-infarcted
area at left anterior descending, first diagonal, and oblique marginal.
Early post-surgery follow-up was uneventful, except for moderate
respiratory distress and surgical suture intolerance unrelated to Peri-
Cord treatment. Post-surgery control echocardiogram showed no signs
of pericarditis. No arrhythmic events were registered during the post-
operative hospital stay. The patient had a one-week post-discharge
visit without significant findings. The PeriCord bioimplant does not
carry immunosuppression requirements due to low immunogenicity
of the WJ-MSCs [26]. At the three-month follow-up, the patient was
alive and without hospital admissions. A three-month cardiac MRI
revealed scar mass of 7¢1 g (scar size = 5¢3%), accounting for ~9% reduc-
tion relative to baseline values. In terms of ventricular volumes, LVFig. 6. Surgical PeriCord implantation. (a) PeriCord batch for implantation, in primary packag
d) Expeditious PeriCord implantation secured by surgical glue droplets at the edges. (e and f
gery and (f) at three-month follow-up.end-diastolic volume was 159 mL and LV end-systolic volume 96 mL,
resulting in reductions of 10% and 9%, respectively, relative to baseline
(Fig. 6E and F).
4. Discussion
Here we describe the complex translational process from preclini-
cal testing to first-in-human patient application of the PeriCord engi-
neered 3D cardiac bioimplant, providing proof of principle that
PeriCord use in humans is feasible and preliminarily safe (Fig. 1). As
we adopt second-generation reparative therapies, such as cardiac tis-
sue engineering, we must be careful to follow regulatory processes to
ensure patient safety, and data validity and reproducibility. We will
next discuss the characteristics of the two components of the Peri-
Cord as compared with other approaches in the pipeline.
First, we will comment on the cells, i.e., the active ingredient. Irre-
spective of origin and clinical purpose, cells used for tissue engineering
applications in humanmust comply with the Guidelines on Human Cell-
Based Medicinal Products (EMEA/CHMP/410869/2006) from the Euro-
pean Medicines Agency, in terms of the cell population’s identity,
potency, purity, viability, safety, efficacy, and suitability for the intended
use. To date, autologous/allogenic hematopoietic stem cells (CD34+/
CD133+), and adult bone marrow/adipose tissue- or WJ-derived MSCs
are the only ATMPs listed on the European Medicines Agency website
(https://www.ema.europa.eu/en/human-regulatory/marketing-authori
sation/advanced-therapies/advanced-therapy-classification/summaries-
scientific-recommendations-classification-advanced-therapy-medicinal-
products. Accessed July 30, 2019) intended for myocardial regeneration.
Of note, none of these are a combined material/cell product. Menasche
et al. pioneered the clinical translation of cardiac tissue engineering usinging at the surgery theatre. (b) Non-revascularisable inferior infarct of the patient. (c and
) Representative short-axis delayed enhancement cardiac MRI obtained (e) before sur-
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fibrin scaffold to treat patients with post-infarct scars [27,28]. However,
ethical restrictions and the need for chronic immunosuppression may
limit the clinical use of these cells.
Clinical grade WJ-MSCs used in the PeriCord bioimplant could be
easily implemented elsewhere. WJ-MSCs exhibit a unique combina-
tion of prenatal and postnatal cell properties, and thus constitute an
alternative to sources of stem cells with significant barriers of
immune rejection, and teratoma formation [29]. This cell type repre-
sents an attractive candidate for a readily available off-the-shelf cel-
lular product for several reasons. WJ-MSCs spontaneously secrete
numerous pro-angiogenic factors with evidence of functional angio-
genic potency in infarcted mammalian hearts [30]. WJ-MSCs are nat-
urally chemoattracted to cardiac tissue, and possess functional ability
to populate the ventricular myocardium [31]. In the mini-swine
model, WJ-MSCs transplanted by a direct injection into the infarct
differentiated into cardiomyocytes and endothelial cells [30]. In addi-
tion, WJ-MSCs can be expanded ex vivo with high karyotype stability
[17], as shown here. Extensive research is being conducted with
induced pluripotent stem cell-derived cardiomyocytes within engi-
neered heart tissue grafts. However, to our knowledge, translation to
human application has not yet been accomplished [32,33].
Secondly, we will discuss the decellularised pericardium, i.e., the
vehicle. In tissue engineering, cells are embedded within a natural or
synthetic scaffold, avoiding the harsh infarcted milieu, while improv-
ing cell retention and survival compared to direct cell injection [12].
The scaffold biomaterial is crucial, and ideally should closely resemble
the physiological cardiac ECM properties. Decellularised cardiac tissues
provide a close match to the native, physiological microenvironment
with minor changes in stiffness and preserving the composition and
three-dimensional framework. Regarding mechanical properties, in a
head-to-head comparison of decellularised scaffolds from myocardial
and pericardial tissues (prepared following a technique similar to that
presently described for the PeriCord), the decellularised pericardial
scaffold performed better [16]. showing preserved macromechanical
and micromechanical pericardial scaffold properties upon the decellu-
larisation and recellularisation processes. Moreover, the pericardial
scaffold demonstrated better cell penetrance and retention, presum-
ably due to bigger pore size [16]. In the context of a preclinical MI
swine model, decellularised pericardial engineered grafts of human
origin integrated with the underlying myocardium, exhibiting signs of
neoinnervation and neovascularisation, and improved cardiac function
post-MI [16]. Similar to WJ-MSCs, allogeneic decellularised pericardial
matrices could be stored for off-the-shelf clinical use [34].
At present, the manufacturing of a PeriCord cardiac bioimplant by
repopulating a pericardial scaffold with WJ-MSCs is labour intensive
and requires multiple steps with pre-specified QCs (Fig. 2). It can be
achieved within eight working hours, producing a bioimplant valid
for clinical use within the following 18 h. The same manufacturing
process will be used for each patient enrolled in the phase I PERI-
SCOPE trial, which is currently in the patient enrolment stage.
The reduction in scar mass observed at three months, although
remarkable, should be interpreted with caution and should not be
used to construe a beneficial functional effect at this point. Indeed,
this patient is a roll-in of the PERISCOPE trial, with a primary end-
point set on safety. Cardiac MRI data are part of the secondary end-
points, and include both 3- and 12-month MRI. Nevertheless, cardiac
MRI accurately measures scarred and viable myocardium and repre-
sents a useful tool for assessing dynamic changes [35]. Relative to the
LV volume changes observed, our current understanding suggests
they likely result from the concomitant CABG than the PeriCord itself;
nevertheless, future implants will shed more light in this issue.
The presently reported PeriCord bioimplant included undifferen-
tiated WJ-MSCs that, at the preclinical level, exhibited abilities to
migrate, transdifferentiate, and induce favourable paracrine effects in
underlying myocardium [2931]. Current available data areinsufficient to determine whether a cardiac tissue engineered
approach requires full ex vivo cardiac myocyte and endothelial differ-
entiation, as has been attempted with cardiac-derived embryonic
stem cells and induced pluripotent stem cells. This remains an open
question for future research.
In conclusion, in this first-in-human preliminary report, we
describe the development and testing of a scalable, clinical-size, Peri-
Cord cardiac bioimplant (Fig. 1). The PeriCord bioimplant has several
advantages. It constitutes a unique combination of two human allo-
geneic biological materials that can be stored off-the-shelf and used
upon request; does not require host immunosuppression; involves
minimal (if any) ethical issues; and incorporates WJ-MSCs, which
exhibit karyotype stability, high immunomodulatory activity, lack of
tumorigenesis, and substantial proliferative and differentiation
potential. Full safety confirmation will be achieved in the ongoing
PERISCOPE trial.
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